Biotech Analysts That Do Well Have a Hybrid Research/Banker Role
Technically speaking this shouldn’t be allowed…. But from every biotech analyst I know their day-to-day is honestly more banker type and that’s why they get paid so much. When you think about the significant amount of raising biotechs do, it makes sense.
Just an observation - I think bio SS can in many ways be a better seat than buyside if you have a path to Analyst at your shop. Thinking risk/reward here
Source? Can you elaborate?
Et dolores libero eum nesciunt dolorem voluptas. Sed eius ad et quae rem modi officia. Soluta dolores ratione aut quibusdam. Aspernatur officia at odit ipsa sunt suscipit.
Repudiandae officia ullam aut a eum quidem. Officia est ab quo quo dignissimos dignissimos.
See All Comments - 100% Free
WSO depends on everyone being able to pitch in when they know something. Unlock with your email and get bonus: 6 financial modeling lessons free ($199 value)
or Unlock with your social account...